Recent Advances in Diagnosis and Therapy of Angioimmunoblastic T Cell Lymphoma

Curr Oncol. 2021 Dec 20;28(6):5480-5498. doi: 10.3390/curroncol28060456.


Angioimmunoblastic T cell lymphoma (AITL) is a common subtype of mature peripheral T cell lymphoma (PTCL). As per the 2016 World Health Organization classification, AITL is now considered as a subtype of nodal T cell lymphoma with follicular helper T cells. The diagnosis is challenging and requires a constellation of clinical, laboratory and histopathological findings. Significant progress in the molecular pathophysiology of AITL has been achieved in the past two decades. Characteristic genomic features have been recognized that could provide a potential platform for better diagnosis and future prognostic models. Frontline therapy for AITL was mainly depending on chemotherapy and the management of relapsed or refractory AITL is still unsatisfactory with a very poor prognosis. Upfront transplantation offers better survival. Novel agents have been introduced recently with promising outcomes. Several clinical trials of combinations using novel agents are underway. Herein, we briefly review recent advances in AITL diagnosis and the evolving treatment landscape.

Keywords: angioimmunoblastic T cell lymphoma; diagnosis; therapy.

Publication types

  • Review

MeSH terms

  • Humans
  • Immunoblastic Lymphadenopathy* / drug therapy
  • Immunoblastic Lymphadenopathy* / therapy
  • Lymphoma, T-Cell* / diagnosis
  • Lymphoma, T-Cell* / genetics
  • Lymphoma, T-Cell* / therapy
  • Lymphoma, T-Cell, Peripheral* / diagnosis
  • Lymphoma, T-Cell, Peripheral* / genetics
  • Lymphoma, T-Cell, Peripheral* / therapy
  • Prognosis